Efficacy and Safety of [²²⁵Ac]Ac-PSMA-617 Augmented [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

• Main Authors: Florian Rosar (Author), Jonas Krause (Author), Mark Bartholomä (Author), Stephan Maus (Author), Tobias Stemler (Author), Ina Hierlmeier (Author), Johannes Linxweiler (Author), Samer Ezziddin (Author), Fadi Khreish (Author)
• Format: Bog
• Udgivet: MDPI AG, 2021-05-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

The use of ²²⁵Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with ¹⁷⁷Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCR...